Psilocybin Therapy for Depression

(PSI-PD Trial)

This trial explores the potential of psilocybin, a compound in certain mushrooms, to help people with Parkinson's Disease who also experience depression. The study evaluates how psilocybin may improve depressive symptoms and overall well-being. Participants will receive psilocybin in a controlled setting across two sessions. Those diagnosed with Parkinson's Disease and experiencing moderate or greater depression might be a good fit for this trial. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important early findings.

You may need to stop taking certain medications before participating in the trial. Specifically, you must avoid medications that could interact with psilocybin, such as MAO inhibitors, certain antidepressants, and opioids, for a specified period before the psilocybin sessions. It's best to discuss your current medications with the research team to determine what's safe.

Research has shown that psilocybin is usually well-tolerated, though some safety concerns exist. In one study, two serious side effects were reported, including a condition where individuals continue to see or hear things after the drug has worn off. Another study found that psilocybin often causes nausea. Despite this, many participants handled the treatment well overall.

Unlike traditional antidepressants that often take weeks to show effects, psilocybin has the potential to provide relief from depression in just a single session. This treatment is unique because it uses psilocybin, a psychedelic compound that targets serotonin receptors in the brain, which might help reset neural pathways associated with depression. Researchers are excited about psilocybin because it offers a novel approach to depression treatment with the possibility of long-lasting positive effects after just one or two doses, compared to daily medication regimens.

Research has shown that psilocybin, a compound in certain mushrooms, may help treat depression. In one study, a single dose significantly reduced depression symptoms for three weeks. Another study found that psilocybin eased symptoms, with effects lasting up to a year for most participants. A review of several studies also found that psilocybin improved depression symptoms. In a long-term follow-up, 67% of patients responded well to the treatment and remained free from depression more than five years later. This trial will evaluate the effects of psilocybin in two separate administration sessions, where participants will receive one dose ranging from low ("microdose") to high in a monitored setting. These findings suggest that psilocybin might offer both quick and lasting relief from depression.¹⁴⁶⁷⁸